Opioid addiction vaccine research gets $3.3 million NIH contract in Montana

The University of Montana received a $3.3 million contract from NIH on July 9 to fund development of a vaccine against opioid addiction, according to ABC Fox Montana.


The vaccine will be developed specifically for fentanyl, though the new technology could also be used for addictive drugs such as heroin or cocaine, said Jay Evans, PhD, director of the university's Center for Translational Medicine. 

The vaccine will generate antibodies that bind to fentanyl in the bloodstream and stop it from crossing the blood brain barrier. Patients addicted to opioids who receive the vaccine will therefore have no positive response to the drugs, making relapses less likely.

Dr. Evans said he hopes to start clinical trials in five years.

More articles on opioids:
400+ US counties at high risk for opioid overdose deaths
CDC data points to 1st drop in overdose deaths since 1990
New Jersey is 1st state to let paramedics administer buprenorphine

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months